Prospective validation of a new method of monitoring minimal residual disease in childhood acute myelogenous leukemia.
about
Monitoring minimal residual disease in acute myeloid leukaemia: a review of the current evolving strategiesMammalian axoneme central pair complex proteins: Broader roles revealed by gene knockout phenotypesAdvancing the Minimal Residual Disease Concept in Acute Myeloid LeukemiaMeasurable residual disease testing in acute myeloid leukaemia.Methylation pattern of preferentially expressed antigen of melanoma in acute myeloid leukemia and myelodysplastic syndromes.Current Approaches in the Treatment of Relapsed and Refractory Acute Myeloid Leukemia.Incorporating measurable ('minimal') residual disease-directed treatment strategies to optimize outcomes in adults with acute myeloid leukemia.Minimal Residual Disease in Acute Myeloid Leukemia.Bone marrow evaluation for diagnosis and monitoring of acute myeloid leukemia.Minimal residual disease monitoring and preemptive immunotherapy in myelodysplastic syndrome after allogeneic hematopoietic stem cell transplantation.Spag6 Mutant Mice Have Defects in Development and Function of Spiral Ganglion Neurons, Apoptosis, and Higher Sensitivity to Paclitaxel.Technical Advances in the Measurement of Residual Disease in Acute Myeloid Leukemia.Mutual epithelium-macrophage dependency in liver carcinogenesis mediated by ST18.The Prognostic Significance of Measurable ("Minimal") Residual Disease in Acute Myeloid Leukemia.Dihydroartemisinin-regulated mRNAs and lncRNAs in chronic myeloid leukemia.Integrated epigenetic and genetic analysis identifies markers of prognostic significance in pediatric acute myeloid leukemia.S100 Proteins in Acute Myeloid Leukemia
P2860
Q26770394-D0D08E8D-33C3-4275-B72A-FA7430163B1DQ26770927-CAD6A15A-228D-452D-AA41-E162ABF5DE7DQ28087291-26AAF246-20DD-4703-A3BE-4E25370ECE7FQ30234914-85399D28-9CBC-4707-9AC5-2C378944AAA4Q33597549-24BAC58B-01EE-4003-8FE7-091499ECD8FEQ35546759-3FAEAD24-A178-4F06-AFE2-8C2A4AFC42E0Q37141503-0AFAEF2C-58BB-4A24-BA36-79EF7A4EF115Q39097771-D3674B0C-DF85-4FED-977E-7F2540BAC244Q39132424-6D0F5EE2-F671-4099-875E-6BE173331430Q39683026-31A4B878-03D6-495B-B3DD-72B882608694Q41448555-69514529-B420-45E0-8134-60678750161BQ41674738-93DD79CC-774B-4622-83E6-B12B22EAE1C9Q42289925-44AE7B6A-97EF-4E51-B719-A57AD45D8915Q47804815-86512CE9-7B64-432F-90A0-F9A1804280EBQ49734919-0D003655-5AE7-4C5A-A177-FAC579F70C89Q55261830-7B99608E-F31C-4FC3-800E-9C1C8F9A3EDAQ58576722-5C644697-DB92-4790-B4CD-9770B7C4D3E2
P2860
Prospective validation of a new method of monitoring minimal residual disease in childhood acute myelogenous leukemia.
description
2014 nî lūn-bûn
@nan
2014 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Prospective validation of a ne ...... od acute myelogenous leukemia.
@ast
Prospective validation of a ne ...... od acute myelogenous leukemia.
@en
type
label
Prospective validation of a ne ...... od acute myelogenous leukemia.
@ast
Prospective validation of a ne ...... od acute myelogenous leukemia.
@en
prefLabel
Prospective validation of a ne ...... od acute myelogenous leukemia.
@ast
Prospective validation of a ne ...... od acute myelogenous leukemia.
@en
P2093
P1476
Prospective validation of a ne ...... od acute myelogenous leukemia.
@en
P2093
Bernd Gruhn
Daniel Steinbach
Dirk Reinhardt
Martin Zimmermann
Peter Bader
Stephan Bartholomae
Ursula Creutzig
P304
P356
10.1158/1078-0432.CCR-14-1999
P407
P577
2014-12-11T00:00:00Z